Literature DB >> 16135660

Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene.

Robin E Pearce1, Jack P Uetrecht, J Steven Leeder.   

Abstract

Conversion of the carbamazepine metabolite, 2-hydroxycarbamazepine, to the potentially reactive species, carbamazepine iminoquinone (CBZ-IQ), has been proposed as a possible bioactivation pathway in the pathogenesis of carbamazepine-induced hypersensitivity. Generation of CBZ-IQ has been proposed to proceed through the intermediate, 2-hydroxyiminostilbene (2-OHIS); however, data suggested that 2-hydroxycarbamazepine is oxidized by cytochromes P450 (P450s) directly to CBZ-IQ, followed by NADPH-mediated reduction to 2-OHIS. In vitro studies were conducted to identify the P450s responsible for converting 2-hydroxycarbamazepine to 2-OHIS and to determine functional consequences of this bioactivation pathway. Formation of 2-OHIS in human liver microsomes (HLMs) was consistent with monophasic, Michaelis-Menten kinetics. The sample-to-sample variation in the rate of 2-OHIS formation correlated significantly (r2 > or = 0.706) with CYP3A4/5 and CYP2B6 activities in a panel of HLMs (n = 10). Studies with a panel of cDNA-expressed enzymes revealed that CYP3A4 preferentially catalyzed 2-OHIS formation; CYP3A4 formed 2-OHIS at a rate >10 times that of other enzymes capable of forming 2-OHIS (CYP1A1, CYP2C19, and CYP3A7). Inhibitors of CYP3A enzymes markedly impaired 2-OHIS formation in HLMs, whereas inhibitors of other P450s resulted in < or = 20% inhibition. Although CYP3A4 was primarily responsible for converting 2-hydroxycarbamazepine to 2-OHIS, neither 2-hydroxycarbamazepine, 2-OHIS, nor CBZ-IQ caused time-dependent inactivation of CYP3A activity. No thiol adducts were formed directly from 2-hydroxycarbamazepine. However, glutathione- and N-acetylcysteine-conjugates were formed with 2-OHIS or CBZ-IQ as substrates. Thus, CYP3A4-dependent secondary oxidation of 2-hydroxycarbamazepine represents a potential carbamazepine bioactivation pathway leading to the formation of thiol-reactive metabolites, intermediates that may play a role in the etiology of idiosyncratic toxicity attributed to carbamazepine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135660     DOI: 10.1124/dmd.105.004861

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  PharmGKB summary: carbamazepine pathway.

Authors:  Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

Review 3.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 4.  Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

Authors:  Chaitali Ghosh; Vikram Puvenna; Jorge Gonzalez-Martinez; Damir Janigro; Nicola Marchi
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

5.  Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study.

Authors:  Chaitali Ghosh; Mohammad Hossain; Addison Spriggs; Arnab Ghosh; Gerald A Grant; Nicola Marchi; Emilio Perucca; Damir Janigro
Journal:  Epilepsia       Date:  2015-02-05       Impact factor: 5.864

6.  CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

Authors:  Monika Pawłowska; Ewa Augustin; Zofia Mazerska
Journal:  Acta Pharmacol Sin       Date:  2013-12-02       Impact factor: 6.150

7.  CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile.

Authors:  Ping Kang; Mingxiang Liao; Michael R Wester; J Steven Leeder; Robin E Pearce; Maria Almira Correia
Journal:  Drug Metab Dispos       Date:  2007-12-20       Impact factor: 3.922

8.  Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.

Authors:  Robin E Pearce; Wei Lu; Yongqiang Wang; Jack P Uetrecht; Maria Almira Correia; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2008-05-07       Impact factor: 3.922

9.  CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.

Authors:  Natasa Djordjevic; Dragana Dragas Milovanovic; Marija Radovanovic; Ivan Radosavljevic; Slobodan Obradovic; Mihajlo Jakovljevic; Dragan Milovanovic; Jasmina R Milovanovic; Slobodan Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-14       Impact factor: 2.953

Review 10.  Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.